Subgroup analysis
Findings from the subgroup analyses are outlined in Table 2. After
categorizing studies on the basis of duration of intervention revealed
that the effect of orlistat on serum uric acid was significantly greater
in trials lasted 6 months (Difference in means: -20.178μmol/l, 95%
CI:-39.646 to 0.710, P=0.04) than 3 months (Difference in means: -12.977
μmol/l 95% CI: -33.400 to 7.445, P=0.21). The subgroup analyses based
on health status revealed that decreased serum uric acid was remarkable
in patients with metabolic syndrome (Difference in means: -33.885
μmol/l, 95% CI: -75.402 to 7.633; P= 0.11) and after that decreased
serum uric acid was significantly remarkable in patients with
hypercholesterolemia (Difference in means: -19.300μmol/l 95% CI:
(-19.502 to -19.098, P=0.00) than other PCOS groups (Difference in
means: -14.402μmol/l 95% CI: (-40.991 to 12.187, P=0.28). Also was
observed serum uric acid increase in NAFLD patients (Difference in
means: 7.461μmol/l 95% CI: -7.470 to 22.392, P=0.32). Moreover,
reduction in serum uric acid after orlistat therapy in studies with
sample size >100 was significantly greater (Difference in
means: -18.310 μmol/l 95% CI: -36.045 to -0.575, P=0.043) than studies
with sample size <100 (Difference in means: -17.105 μmol/l
95% CI: -36.745 to 2.535, P=0.08). Stratified on the basis of items
were taken with orlistat, a significant reduction was observed in trials
performed on patients were taken orlistat with low calorie diet
(Difference in means: -35.949 μmol/l 95% CI: -66.772 to -5.127, P=0.02)
in comparison with other groups.